ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

FDA Considering Ways To Improve Process Of Secondary Approvals Of Cancer Drugs

November 1, 1991

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Business & Regulatory Report March edition (8 pages) included.

March 19, 2004

Moloney Out As Viral Oncology Chief, Names “Acting Assistant Director” Of NCI By Upton

January 6, 1978

Black, Hispanic Cancer Initiatives to Be Funded, Formed

June 7, 1991

Two Drugs Combined Better Than One Alone, Study Finds

February 27, 2009